

BIO REFERENCE LABORATORIES INC
Form 10-Q
June 06, 2008

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the quarterly period ended April 30, 2008

Or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECUTRIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number 0-15266

BIO-REFERENCE LABORATORIES, INC.

(Exact name of registrant as specified in its charter)

NEW JERSEY

22-2405059

Edgar Filing: BIO REFERENCE LABORATORIES INC - Form 10-Q

(State or other jurisdiction of incorporation or organization)

(IRS Employer Identification No.)

481 Edward H. Ross Drive, Elmwood Park, NJ
(Address of principal executive offices)

07407
(Zip Code)

(201) 791-2600

(Registrant's telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes No

Indicate by checkmark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer, and smaller reporting company in Rule 12b-2 of the Act. (Check one):

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes No

APPLICABLE ONLY TO CORPORATE ISSUERS:

Indicate the number of shares outstanding of the issuer's common stock, as of the latest practicable date: 13,784,640 shares of Common Stock (\$.01 par value) at June 6, 2008.

BIO-REFERENCE LABORATORIES, INC.

FORM 10-Q

April 30, 2008

INDEX

| | Page |
|--|-------------|
| <u>PART I. FINANCIAL INFORMATION</u> | |
| <u>Item 1. Financial Statements</u> | |
| <u>Consolidated Balance Sheets as of April 30, 2008 (unaudited) and October 31, 2007.</u> | 2 |
| <u>Consolidated Statements of Operations for the three months and six months ended April 30, 2008 and April 30, 2007 (unaudited)</u> | 4 |
| <u>Consolidated Statements of Cash Flows (unaudited) for the six months ended April 30, 2008 and April 30, 2007</u> | 5 |
| <u>Notes to consolidated financial statements (unaudited)</u> | 7 |
| <u>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u> | 10 |
| <u>Item 3. Quantitative and Qualitative Disclosures About Market Risk</u> | 14 |
| <u>Item 4. Controls and Procedures</u> | 14 |
| <u>PART II. OTHER INFORMATION</u> | 14 |
| <u>Item 6. Exhibits</u> | 14 |
| <u>Signatures</u> | 15 |
| <u>Certifications</u> | 16 |

Item 1

BIO-REFERENCE LABORATORIES, INC. AND SUBSIDIARIES**PART I FINANCIAL INFORMATION****CONSOLIDATED BALANCE SHEETS**

[Dollars In Thousands Except Per Share Data, Or Unless Otherwise Noted]

ASSETS

| | April 30, 2008 (Unaudited) | October 31, 2007 |
|--|----------------------------------|---------------------|
| <u>CURRENT ASSETS:</u> | | |
| Cash and Cash Equivalents | \$ 10,059 | \$ 11,897 |
| Accounts Receivable - Net | 90,444 | 86,018 |
| Inventory | 3,681 | 3,120 |
| Other Current Assets | 2,462 | 1,443 |
| Deferred Tax Assets | 6,201 | 6,019 |
| <u>TOTAL CURRENT ASSETS</u> | 112,847 | 108,497 |
| <u>PROPERTY AND EQUIPMENT - AT COST</u> | 36,416 | 33,791 |
| <u>LESS: Accumulated Depreciation</u> | 14,086 | 13,266 |
| <u>PROPERTY AND EQUIPMENT - NET</u> | 22,330 | 20,525 |
| <u>OTHER ASSETS:</u> | | |
| Deposits | 546 | 516 |
| Goodwill - Net | 16,681 | 16,681 |
| Intangible Assets - Net | 5,979 | 6,550 |
| Other Assets | 1,174 | 1,054 |
| Deferred Tax Asset | 743 | 751 |
| <u>TOTAL OTHER ASSETS</u> | 25,123 | 25,552 |
| <u>TOTAL ASSETS</u> | \$ 160,300 | \$ 154,574 |

The Accompanying Notes are an Integral Part of These Consolidated Financial Statements.

BIO-REFERENCE LABORATORIES, INC. AND SUBSIDIARIES**CONSOLIDATED BALANCE SHEETS**

[Dollars In Thousands Except Per Share Data, Or Unless Otherwise Noted]

LIABILITIES AND SHAREHOLDERS EQUITY

| | April 30, 2008 (Unaudited) | October 31, 2007 |
|---|----------------------------------|---------------------|
| <u>CURRENT LIABILITIES:</u> | | |
| Accounts Payable | \$ 25,162 | \$ 24,576 |
| Accrued Salaries and Commissions Payable | 5,444 | 5,214 |
| Accrued Taxes and Expenses | 4,059 | 3,583 |
| Revolving Note Payable - Bank | 20,568 | 23,252 |
| Current Maturities of Long-Term Debt | 1,164 | 1,154 |
| Capital Lease Obligations - Short-Term Portion | 2,216 | 1,971 |
| <u>TOTAL CURRENT LIABILITIES</u> | 58,613 | 59,750 |
| <u>LONG-TERM LIABILITIES</u> | | |
| Capital Lease Obligations - Long-Term Portion | 3,360 | 2,509 |
| Long - Term Debt - Net of Current Portion | 6,320 | 6,766 |
| Deferred Tax Liabilities | 406 | 282 |
| <u>TOTAL LONG-TERM LIABILITIES</u> | 10,086 | 9,557 |
| <u>COMMITMENTS AND CONTINGENCIES</u> | | |
| <u>SHAREHOLDERS EQUITY</u> | | |
| Preferred Stock \$.10 Par Value; Authorized 1,059,589 shares, None Issued | | |
| Series A - Senior Preferred Stock, \$.10 Par Value; Authorized Issued and Outstanding; None | | |
| Series A - Junior Participating Preferred Stock, \$.10 Par Value, Authorized 3,000 Shares; None Issued | | |
| Common Stock, \$.01 Par Value; Authorized 35,000,000 shares: Issued and Outstanding 13,784,640 and 13,748,634 at April 30, 2008 and at October 31, 2007, respectively | 138 | 138 |
| Additional Paid-In Capital | 42,128 | 41,435 |
| Retained Earnings | 49,335 | 43,700 |
| Totals | 91,601 | 85,273 |
| Deferred Compensation | | (6) |
| <u>TOTAL SHAREHOLDERS EQUITY</u> | 91,601 | 85,267 |
| <u>TOTAL LIABILITIES AND SHAREHOLDERS EQUITY</u> | \$ 160,300 | \$ 154,574 |

The Accompanying Notes are an Integral Part of These Consolidated Financial Statements.

BIO-REFERENCE LABORATORIES, INC. AND SUBSIDIARIES**CONSOLIDATED STATEMENTS OF OPERATIONS**

[Dollars In Thousands Except Per Share Data, Or Unless Otherwise Noted]

[UNAUDITED]

| | Three months ended April 30, | | Six months ended April 30, | |
|---|---------------------------------|-------------------|-------------------------------|-------------------|
| | 2008 | 2007 | 2008 | 2007 |
| NET REVENUES: | \$ 75,180 | \$ 60,953 | \$ 142,059 | \$ 114,675 |
| COST OF SERVICES: | | | | |
| Depreciation and Amortization | 1,407 | 1,057 | 2,783 | 1,960 |
| Employee Related Expenses | 18,384 | 13,895 | 34,859 | 27,244 |
| Reagents and Laboratory Supplies | 11,736 | 8,963 | 21,992 | 16,844 |
| Other Cost of Services | 7,471 | 6,514 | 14,592 | 11,910 |
| TOTAL COST OF SERVICES | 38,998 | 30,429 | 74,226 | 57,958 |
| GROSS PROFIT ON REVENUES | 36,182 | 30,524 | 67,833 | 56,717 |
| General and Administrative Expenses: | | | | |
| Depreciation and Amortization | 586 | 634 | 1,143 | 1,248 |
| General and Administrative Expenses | 19,488 | 16,101 | 37,116 | 31,163 |
| Bad Debt Expense | 9,893 | 7,930 | 19,095 | 14,859 |
| TOTAL GENERAL AND ADMINISTRATIVE EXPENSES | 29,967 | 24,665 | 57,354 | 47,270 |
| INCOME FROM OPERATIONS | 6,215 | 5,859 | 10,479 | 9,447 |
| OTHER (INCOME) EXPENSE: | | | | |
| Interest Expense | 584 | 589 | 1,186 | 1,106 |
| Interest Income | (67) | (62) | (148) | (113) |
| TOTAL OTHER EXPENSES - NET | 517 | 527 | 1,038 | 993 |
| INCOME BEFORE INCOME TAXES | 5,698 | 5,332 | 9,441 | 8,454 |
| Provision for Income Taxes | 2,271 | 2,174 | 3,806 | 3,330 |
| NET INCOME | \$ 3,427 | \$ 3,158 | \$ 5,635 | \$ 5,124 |
| NET INCOME PER COMMON SHARE - BASIC: | \$ 0.25 | \$ 0.23 | \$ 0.41 | \$ 0.38 |
| WEIGHTED AVERAGE NUMBER OF SHARES - BASIC: | 13,783,140 | 13,634,367 | 13,774,146 | 13,608,591 |
| NET INCOME PER COMMON SHARE - DILUTED: | \$ 0.25 | \$ 0.23 | \$ 0.40 | \$ 0.37 |
| WEIGHTED AVERAGE NUMBER OF SHARES - DILUTED: | 13,984,890 | 13,884,502 | 13,993,553 | 13,845,177 |

Edgar Filing: BIO REFERENCE LABORATORIES INC - Form 10-Q

The Accompanying Notes are an Integral Part of These Consolidated Financial Statements

BIO-REFERENCE LABORATORIES, INC. AND SUBSIDIARIES**CONSOLIDATED STATEMENTS OF CASH FLOWS**

[Dollars In Thousands Except Per Share Data]

[UNAUDITED]

| | Six months ended April 30 | |
|---|------------------------------|------------------|
| | 2008 | 2007 |
| <u>OPERATING ACTIVITIES:</u> | | |
| Net Income | \$ 5,635 | \$ 5,124 |
| Adjustments to Reconcile Net Income to Cash Provided by Operating Activities: | | |
| Depreciation and Amortization | 3,926 | 3,208 |
| Amortization of Deferred Compensation | 6 | 59 |
| Deferred Income Tax (Benefit) | (50) | (1,924) |
| Stock Based Compensation | 86 | |
| Loss on Disposal of Fixed Assets | 280 | 51 |
| Change in Assets and Liabilities, (Increase) Decrease in: | | |
| Accounts Receivable | (5,393) | (14,872) |
| Provision for Doubtful Accounts | 967 | 4,742 |
| Inventory | (561) | (455) |
| Other Current Assets | (1,019) | (236) |
| Other Assets and Deposits | (150) | 41 |
| Increase (Decrease) in: | | |
| Accounts Payable and Accrued Liabilities | 3,209 | 3,904 |
| <u>NET CASH - OPERATING ACTIVITIES</u> | 6,936 | (358) |
| <u>INVESTING ACTIVITIES:</u> | | |
| Acquisition of Equipment and Leasehold Improvements | (2,847) | (3,284) |
| Business Acquisitions and Related Costs | (1,917) | |
| Acquisition of Intangible Assets | | (28) |
| <u>NET CASH - INVESTING ACTIVITIES</u> | (4,764) | (3,312) |
| <u>FINANCING ACTIVITIES:</u> | | |
| Payments of Long-Term Debt | (436) | (562) |
| Payments of Capital Lease Obligations | (1,497) | (1,346) |
| (Decrease) Increase in Revolving Line of Credit - Net | (2,684) | 6,631 |
| Proceeds from Exercise of Options | 607 | 1,073 |
| <u>NET CASH - FINANCING ACTIVITIES</u> | (4,010) | 5,796 |
| <u>NET INCREASE IN CASH AND CASH EQUIVALENTS</u> | (1,838) | 2,126 |
| <u>CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIODS</u> | 11,897 | 8,954 |
| <u>CASH AND CASH EQUIVALENTS AT END OF PERIODS</u> | \$ 10,059 | \$ 11,080 |
| <u>SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</u> | | |
| Cash paid during the period for: | | |
| Interest | \$ 1,245 | \$ 1,121 |
| Income Taxes | \$ 4,657 | \$ 3,904 |

The Accompanying Notes are an Integral Part of These Consolidated Financial Statements.

SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:

[Dollars In Thousands Except Per Share Data]

During the six month period ended April 30, 2008 and April 30, 2007 the Company entered into capital leases totaling \$2,593 and \$1,155 respectively.

During the six month period ended April 30, 2008 and April 30, 2007, the Company wrote-off approximately \$2,815 and \$2,058 of furniture and equipment that were fully depreciated.

During the six month period ended April 30, 2008 and April 30, 2007 the Company wrote-off approximately \$2,333 and \$0 of intangible assets that were fully amortized.

During the six month period ended April 30, 2008 and April 30, 2007 the Company recorded approximately \$86 and \$0 of stock based compensation expense under the FAS123R related to granting of stock options and shares of company's stock.

During the six month period ended April 30, 2008 and April 30, 2007, the Company recorded a tax benefit effect on the exercise of non-qualified stock options of \$0 and \$229 as an increase to Paid-In Capital and the Deferred Tax Asset.

During the six month period ended April 30, 2008 and April 30, 2007, the Company financed the purchase of equipment through a term note of approximately \$0 and \$4,100.

The Accompanying Notes are an Integral Part of These Consolidated Financial Statements.

BIO-REFERENCE LABORATORIES, INC. AND SUBSIDIARIES**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS****[Dollars In Thousands Except Per Share Data, Or Unless Otherwise Noted]****(UNAUDITED)**

[1] In the opinion of management, the accompanying unaudited consolidated financial statements reflect all adjustments [consisting only of normal adjustments and recurring accruals] which are necessary to present a fair statement of the results for the interim periods presented but do not include all of the information and footnotes required by generally accepted accounting principles in the United States of America for complete financial statements.

[2] The results of operations for the six months ended April 30, 2008 are not necessarily indicative of the results to be expected for the entire year.

[3] The consolidated financial statements and notes thereto should be read in conjunction with the consolidated financial statements and notes for the year ended October 31, 2007 as filed with the Securities and Exchange Commission in the Company's Annual Report on Form 10-K.

[4] The significant accounting policies followed by the Company are set forth in Note 2 to the Company's consolidated financial statements in the October 31, 2007 Form 10-K.

[5] Certain prior year amounts have been reclassified to conform with the current year presentation.

[6] Service revenues are principally generated from laboratory testing services including chemical diagnostic tests such as blood analysis, urine analysis and genetic testing among others. Net service revenues are recognized at the time the testing services are performed and are reported at their estimated net realizable amounts. Net realizable amounts from patients, third party payors and others for services rendered, are accrued on an estimated basis in the period the related services are rendered, and are adjusted in subsequent periods based upon an analysis of the Company's collection experience from each category of payor group as well as prospectively determined contractual adjustments and discounts with third party payors. Differences between these adjustments and any subsequent revisions are included in the statement of operations in which the revisions are made and are disclosed, if material. Applying this methodology and aggregating its collection experience from all payor groups, the Company has not been required to record an adjustment related to revenue recorded in prior periods that was material in nature. Revenues on the statements of operations are net of the following amounts for allowances and discounts.

| | Three Months Ended April 30 [Unaudited] | | Six Months Ended April 30 [Unaudited] | |
|-------------------|---|-----------|---|-----------|
| | 2008 | 2007 | 2008 | 2007 |
| Medicare/Medicaid | \$ 48,338 | \$ 35,465 | \$ 91,861 | \$ 69,165 |
| Other | 131,542 | 92,960 | 245,280 | 167,271 |

Edgar Filing: BIO REFERENCE LABORATORIES INC - Form 10-Q

\$ 179,880 \$ 128,425 \$ 337,141 \$ 236,436

A number of proposals for legislation or regulation continue to be under discussion which could have the effect of substantially reducing Medicare reimbursements for clinical laboratories or introducing cost sharing to beneficiaries. Depending upon the nature of regulatory action, if any, which is taken and the content of legislation, if any, which is adopted, the Company could experience a significant decrease in revenues from Medicare and Medicaid, which could have a material adverse effect on the Company. The Company is unable to predict, however, the extent to which such actions will be taken.

[7] An allowance for contractual credits and discounts is estimated by payor group and determined based upon a review of the reimbursement policies and subsequent collections from the different types of payors. The Company has not been required to record an adjustment in a subsequent period related to revenue recorded in a prior period, which was material in nature. Agings of accounts receivable are monitored by billing personnel and follow-up activities are conducted as necessary. Bad debt expense is recorded within selling, general and administrative expenses as a percentage of sales considered necessary to maintain an allowance for doubtful accounts at an appropriate level, based on the Company's experience with its accounts receivable. The Company writes off receivables against the allowance for doubtful accounts when they are deemed to be uncollectible. For client billing, accounts are written off when all reasonable collection efforts prove to be unsuccessful. Patient accounts are written off after the normal dunning cycle has occurred, which may include transfer to a third party collection agency. Third party accounts are written off when they exceed the payer's timely filing limits. Accounts Receivable on the balance sheets are net of the following amounts for contractual credits and doubtful accounts:

| | [Unaudited] April 30, 2008 | October 31, 2007 |
|-------------------------------|-------------------------------|------------------|
| Contractual Credits/Discounts | \$ 81,498 | \$ 79,257 |
| Doubtful Accounts | 12,609 | 11,643 |
| | \$ 94,107 | \$ 90,900 |

[8] In May 2008, FASB issued two new Financial Accounting Standards No. 162 The Hierarchy of Generally Accepted Accounting Principles and No. 163 Accounting for Financial Guarantee Insurance Contracts an interpretation of FASB Statement No. 60 .

Edgar Filing: BIO REFERENCE LABORATORIES INC - Form 10-Q

FAS #162 identifies the sources of accounting principles and the framework for selecting the principles to be used in the preparation of financial statements of nongovernmental entities that are presented in conformity with generally accepted accounting principles (GAAP) in the United States (the GAAP hierarchy). This Statement is effective 60 days following the SEC's approval of the Public Company Accounting Oversight Board amendments to AU Section 411, *The Meaning of Present Fairly in Conformity With Generally Accepted Accounting Principles*. This statement is not expected to have a material impact on the reporting of our results of operations.

FAS #163 is primarily geared towards financial guarantee insurance contracts by insurance enterprises. It is not expected to have any material effect on the reporting of our results of operations.

In March 2008 FASB issued Financial Accounting Standards No. 161, *Disclosures about Derivative Instruments and Hedging Activities* an amendment of FASB Statement No. 133. This statement is effective for financial statements issued for fiscal years end interim periods beginning after November 15, 2008, with early application encouraged.. This Statement changes the disclosure requirements for derivative instruments and hedging activities. This statement is not expected to have a material impact on the reporting of our results of operations.

In February 1, 2008, FASB issued FASB Staff Position (FSP) Fin 48-2. FSP FIN 48-2 amends FIN 48 to defer its effective date for nonpublic and pass through entities. This is not expected to have any effect on the Company's consolidated financial statements as the Company does not currently employ any pass through entities.

In December 2007, the FASB issued Financial Accounting Standards No. 160, *Noncontrolling Interests in Consolidated Financial Statements* an amendment of ARB No. 51. This statement is effective for fiscal years, and interim periods within those fiscal years, beginning on or after December 15, 2008, with earlier adoption prohibited. This statement requires the recognition of a noncontrolling interest (minority interest) as equity in the consolidated financial statements and separate from the parent's equity. The amount of net income attributable to the noncontrolling interest will be included in consolidated net income on the face of the income statement. It also amends certain of ARB No. 51's consolidation procedures for consistency with the requirements of SFAS 141(R). This statement also includes expanded disclosure requirements regarding the interests of the parent and its noncontrolling interest. We are currently evaluating this new statement and anticipate that the statement will not have a significant impact on the reporting of our results of operations.

[9] The following disclosures present certain information on the Company's intangible assets as of April 30, 2008 (Unaudited) and October 31, 2007. All intangible assets are being amortized over their estimated useful lives, as indicated below, with no estimated residual value.

[Unaudited]

April 30, 2008

| Intangible Asset | Weighted-Average Amortization Period | Cost | Accumulated Amortization | Net of Accumulated Amortization |
|--------------------------|--|----------|-----------------------------|---------------------------------------|
| Customer Lists | 20 | \$ 4,873 | \$ 1,801 | \$ 3,072 |
| Covenants Not-to-Compete | 5 | 4,205 | 1,348 | 2,857 |
| Patent | 17 | 156 | 106 | 50 |

Edgar Filing: BIO REFERENCE LABORATORIES INC - Form 10-Q

| | | | | | | |
|--------|----|-------|----|-------|----|-------|
| Totals | \$ | 9,234 | \$ | 3,255 | \$ | 5,979 |
|--------|----|-------|----|-------|----|-------|

October 31, 2007

| Intangible Asset | Weighted-Average Amortization Period | Cost | Accumulated Amortization | Net of Accumulated Amortization |
|--------------------------|--|----------|-----------------------------|---------------------------------------|
| Customer Lists | 20 | \$ 5,045 | \$ 1,828 | \$ 3,217 |
| Covenants Not-to-Compete | 5 | 4,205 | 927 | 3,278 |
| Patent | 17 | 156 | 101 | 55 |
| Totals | | \$ 9,406 | \$ 2,856 | \$ 6,550 |

The aggregate intangible amortization expense for the three months ended April 30, 2008 and 2007 was \$285 and \$333, respectively and for the six months ended April 30, 2008 and 2007 was \$571 and \$667, respectively. The estimated intangible asset amortization expense for the fiscal year ending October 31, 2008 and thereafter is as follows:

| Year Ended October 31, | Amortization Expense |
|---------------------------|-------------------------|
| 2008 | \$ 1,135 |
| 2009 | 1,110 |
| 2010 | 1,085 |
| 2011 | 973 |
| 2012 | 202 |
| Thereafter | 1,474 |
| Total | \$ 5,979 |

[10] In October 2007, the Company entered into an amended revolving note payable loan agreement with PNC Bank. The maximum amount of the credit line available to the Company is the lesser of (i) \$30,000 or (ii) 50% of the Company's qualified accounts receivable [as defined in the agreement]. The amendment to the Loan and Security Agreement provides for interest on advances to be subject to the bank's prime rate or Eurodollar rate of interest plus, in certain instances, an additional interest percentage. The additional interest percentage charges on Eurodollar borrowings range from 1% to 4% and are determined based upon certain financial ratios achieved by the Company. At April 30, 2008, the Company had elected to have \$20,000 of the total advances outstanding converted into a Eurodollar rate loan with a variable interest rate of 4.41% at April 30, 2008. The remaining outstanding advances during that period were subject to the bank's prime rate of interest. At April 30, 2008, advances of \$568 were subject to interest at the prime rate. As of April 30, 2008, the bank's prime rate of interest was 5.00%. The credit line is collateralized by substantially all of the Company's assets. The line of credit is available through October 2008 and may be extended for annual periods by mutual consent, thereafter. The terms of this agreement contain, among other provisions, requirements for maintaining defined levels of capital expenditures, fixed charge coverage, insurance coverage and the prohibition of the payment by the Company of cash dividends. As of April 30, 2008, the Company utilized \$20,568 and had \$9,432 of available unused credit under this revolving note payable loan agreement.

Effective as of October 31, 2007, we executed a fifth amendment to the Loan Agreement formalizing the repayment terms of the \$5 million term loan from PNC Bank used by our wholly-owned BRLI No. 2 Acquisition Corp. subsidiary to fund the \$5 million acquisition cash payment in connection with its purchase of the operating assets of GeneDx, Inc. The term loan is evidenced by a secured promissory note payable over a six year term in equal monthly principal payments of approximately \$69, plus interest at an annual rate of 6.85%. The balance on this note as of April 30, 2008 is approximately \$3,750.

Pursuant to this agreement the Company made a cash payment to the prior owners of GeneDx as certain financial goals were achieved of \$1,917 and 11,548 shares of BRLI's common stock during the period ended January 31, 2008.

In January 2007, the Company issued a ten year term note of \$4,100 for the financing of equipment. The note is payable in equal monthly installments of approximately \$47 including principal and interest, with payment commencing on March 1, 2007 at an effective interest rate of 6.63% per annum. The balance on this note as of April 30, 2008 is approximately \$3,723.

[11] The provision for income taxes for the three months ended April 30, 2008, consists of a current tax provision of \$1,809 and a deferred tax expense of \$462. The provision for income taxes for the six months ended April 30, 2008, consists of a current tax provision of \$3,856 and a deferred tax benefit of \$50. On April 30, 2008, the Company had a current deferred tax asset of \$6,201 included in other current assets and a long-term deferred tax asset of \$743 included in other assets along with a long-term deferred tax liability of \$406 included in long-term liabilities. The provision for income taxes for the three months ended April 30, 2007, consists of a current tax provision of \$3,070 and a deferred tax benefit of \$896. The provision for income taxes for the six months ended April 30, 2007 consists of a current tax of \$5,484 and a deferred tax benefit of \$2,154.

Edgar Filing: BIO REFERENCE LABORATORIES INC - Form 10-Q

[12] Subsequent Event In May of 2008, the Company executed a sixth amendment to the loan agreement with PNC Bank (1) increasing the maximum revolving advance limit to \$40,000 (2) increasing the capital expenditure limit to \$15,000 during any fiscal year and (3) extending the term until October 31, 2012.

Item 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

RESULTS OF OPERATIONS

COMPARISON OF SECOND QUARTER 2008 VS SECOND QUARTER 2007

[In Thousands Except Per Share Data, Or Unless Otherwise Noted]

NET REVENUES:

Net revenues for the three month period ended April 30, 2007 were \$60,953 as compared to \$75,180 for the three month period ended April 30, 2008; which represents a 23% increase in net revenues. This increase is due to a 14% increase in patient counts and an increase in revenue per patient of 8% due to a shift in business to higher reimbursement esoteric testing which continues to be the principal driver in net revenue per patient.

The number of patients serviced during the three month period ended April 30, 2008 was 1,050 thousand which was 14% greater when compared to the prior fiscal year's three month period. Net revenue per patient for the three month period ended April 30, 2007 was \$65.59 compared to net revenue per patient of \$70.95 for the three month period ended April 30, 2008, an increase of \$5.37 or 8%.

COST OF SERVICES:

Cost of Services increased from \$30,429 for the three month period ended April 30, 2007 to \$38,998 for the three month period ended April 30, 2008, an increase of \$8,569 or 28%. This increase is 5% greater than the increase in net revenues of 23%. Employee related expenses increased from \$13,895 for the period ended April 30, 2007 to \$18,384 for the period ended April 30, 2008 an increase of 32%, driven by increases in technical, professional and semi-technical salaries. In addition, pick-up and delivery vehicle operating expenses (energy related costs) increased 28% year over year. We anticipate that these costs will continue this pattern for the remainder of the fiscal year.

GROSS PROFITS:

Gross profits increased from \$30,524 for the three month period ended April 30, 2007 to \$36,182 for the three month period ended April 30, 2008; an increase of \$5,658 or 19%. Gross profit margin decreased from 50% in fiscal 2007 to 48% in fiscal 2008.

GENERAL AND ADMINISTRATIVE EXPENSES:

General and administrative expenses for the three month period ending April 30, 2007 were \$24,665 as compared to \$29,967 for the quarter ended April 30, 2008, an increase of \$5,302 or 21%. This increase is in line with the increase in net revenues. However, marketing expenses increased \$2,047 or 42% and occupancy expenses increased 446 or 28%. While these categories increased dramatically, they are in line with expectations.

INTEREST EXPENSE:

Interest expense decreased to \$584 during the three month period ending April 30, 2008 from \$589 during the three month period ended April 30, 2007. This decrease is due to a decrease in the utilization of our PNC Bank line of credit and lower interest rates. Management believes that this trend will continue in the short-term due to the decrease in interest rates.

INCOME:

We realized net income of \$3,158 for the three month period ended April 30, 2007, as compared to \$3,427 for the three month period ended April 30, 2008, an increase of \$269 or 9%. Pre-tax income for the period ended April 30, 2007 was \$5,332, compared to \$5,698 for the three month period ended April 30, 2008, an increase of \$366 or 7%. The provision for income taxes increased from \$2,174 for the three month period ended April 30, 2007 to \$2,271 for the period ended April 30, 2008.

SIX MONTHS 2008 COMPARED TO SIX MONTHS 2007

NET REVENUES:

Net Revenues for the six month period ended April 30, 2007 were \$114,675 as compared to \$142,059 for the six month period ended April 30, 2008; this represents a 24% increase in net revenues. This increase is due to a 15% increase in patient counts and revenue per patient increased 9%.

The number of patients serviced during the six month period ended April 30, 2008 was 2,013 which was 15% greater when compared to the prior fiscal year's six month period. Net revenue per patient for the six month period ended April 30, 2007 was \$64.46, compared to net revenue per patient for the six month period ended April 30, 2008 of \$69.94, an increase of \$5.48 or 9%.

COST OF SERVICES:

Edgar Filing: BIO REFERENCE LABORATORIES INC - Form 10-Q

Cost of Services increased to \$74,226 for the six month period ended April 30, 2008 from \$57,958 for the six month period ended April 30, 2007. This represents a 28% increase in direct operating costs. This increase is 4% greater than the increase in net revenues. Employee related expenses increased from \$27,244 for the period ended April 30, 2007 to \$34,859 for the period ended April 30, 2008 an increase of 28%, driven by increases in technical, professional and semi-technical salaries. In addition, pick-up and delivery vehicle operating expenses (energy related costs) increased 49% year over year. We anticipate that these costs will continue this pattern for the remainder of the fiscal year.

GROSS PROFITS:

Gross profits on net revenues, increased to \$67,833 for the six month period ended April 30, 2008 from \$56,717 for the six month period ended April 30, 2007; an increase of \$11,116 (20%). Gross profit margins decreased from 49% in FY2007 to 48% in FY2008.

GENERAL AND ADMINISTRATIVE EXPENSES:

General and administrative expenses for the six month period ended April 30, 2007 were \$47,270 as compared to \$57,354 for the six month period ended April 30, 2008. This represents an increase of \$10,084 or 21%. This increase is in line with the increase in net revenues. However, marketing expenses increased \$3,291 or 34% and occupancy expenses increased \$876 or 28%. While these expense categories increased dramatically, they are in line with our growth expectations.

INTEREST EXPENSE:

Interest expense increased to \$1,186 during the six month period ending April 30, 2008 as compared to \$1,106 during the six month period ending April 30, 2007, an increase of \$80. The relatively marginal increase was due to a further decrease in the utilization of the PNC Bank line of credit and additional reductions of interest rates during the second quarter. Management believes that this trend will continue in the short-term due to the decrease in interest rates.

INCOME:

We realized net income of \$5,635 for the six months ended April 30, 2008 as compared to \$5,124 for the six month period ended April 30, 2007, an increase of 10%. Pre-tax income for the six month period ended April 30, 2007 was \$8,454, as compared to \$9,441 for the six month period ended April 30, 2008, an increase of \$987 (12%). The provision for income taxes increased from \$3,330 for the six month period ended April 30, 2007 to \$3,806 for the six month period ended April 30, 2008.

LIQUIDITY AND CAPITAL RESOURCES [In Thousands]:

Our working capital at April 30, 2008 was \$54,234 as compared to \$48,747 at October 31, 2007 an increase of \$5,487. Our cash position decreased by \$1,838 during the current period. This was caused by the cash payment to the prior owners of GeneDx of \$1,917. We reduced our short term debt by \$2,684 and repaid \$1,933 in existing debt. We had current liabilities of \$58,613 at April 30, 2008. We generated \$6,936 in cash from operations, compared to utilizing \$358 in cash from operations for the quarter ended April 30, 2007, an overall increase of \$7,294 in cash generated from operations year over year.

Edgar Filing: BIO REFERENCE LABORATORIES INC - Form 10-Q

Accounts receivable, net of allowance for doubtful accounts, totaled \$90,444 at April 30, 2008, an increase of \$4,426 from October 31, 2007 or 5%. This increase was primarily attributable to increased revenue. Cash collected during the three month period ended April 30, 2008 increased 33% over the comparable three month period in 2007.

Credit risk with respect to accounts receivable is generally diversified due to the large number of patients comprising our client base. We have significant receivable balances with government payors and various insurance carriers. Generally, we do not require collateral or other security to support customer receivables. However, we continually monitor and evaluate our client acceptance and collection procedures to minimize potential credit risks associated with our accounts receivable and establish an allowance for uncollectible accounts. As a consequence, we believe that our accounts receivable credit risk exposure beyond such allowance is not material to the financial statements.

A number of proposals for legislation continue to be under discussion which could substantially reduce Medicare and Medicaid reimbursements to clinical laboratories. Depending upon the nature of regulatory action, and the content of legislation, we could experience a significant decrease in revenues from Medicare and Medicaid, which could have a material adverse effect on us. We are unable to predict, however, the extent to which such actions will be taken.

Billing for laboratory services is complicated and we must bill various payors, such as the individual, the insurance company, the government (federal or state), the private company or the health clinic. Other factors that may complicate billing include:

- Differences between fee schedules and reimbursement rates.
- Incomplete or inaccurate billing information as provided by the physician.
- Disparity in coverage and information requirements.
- Disputes with payors.
- Internal and external compliance policies and procedures.

Significant costs are incurred as a result of our participation in government programs since billing and reimbursement for laboratory tests are subject to complex regulations. We perform the requested tests and report the results whether the information is correct or not or even missing. This adds to the complexity and slows the collection process and increases the aging of our accounts receivable (A/R). When patient invoices are not collected in a timely manner the item is written off to the allowance. Days Sales Outstanding (DSO) for the period ended April 30, 2008 was 109 days, a decrease of 7 days, or 6%, from the 116 days that we reported for the period ended April 30, 2007.

In October 2007, the Company entered into an amended revolving note payable loan agreement with PNC Bank. The maximum amount of the credit line available to the Company is the lesser of (i) \$30,000 or (ii) 50% of the Company's qualified accounts receivable [as defined in the agreement]. The amendment to the Loan and Security Agreement provides for interest on advances to be subject to the bank's prime rate or

Edgar Filing: BIO REFERENCE LABORATORIES INC - Form 10-Q

Eurodollar rate of interest plus, in certain instances, an additional interest percentage. The additional interest percentage charges on Eurodollar borrowings range from 1% to 4% and are determined based upon certain financial ratios achieved by the Company. At April 30, 2008, the Company had elected to have \$20,000 of the total advances outstanding converted into a Eurodollar rate loan with a variable interest rate of 4.41% at April 30, 2008. The remaining outstanding advances during that period were subject to the bank's prime rate of interest. At April 30, 2008, advances of \$568 were subject to interest at the prime rate. As of April 30, 2008, the bank's prime rate of interest was 5.00%. The credit line is collateralized by substantially all of the Company's assets. The line of credit is available through October 2008 and may be extended for annual periods by mutual consent, thereafter. The terms of this agreement contain, among other provisions, requirements for maintaining defined levels of capital expenditures, fixed charge coverage, insurance coverage and the prohibition of the payment by the Company of cash dividends. As of April 30, 2008, the Company utilized \$20,528 and had \$9,472 of available unused credit under this revolving note payable loan agreement.

Effective as of October 31, 2007, we executed a fifth amendment to the Loan Agreement formalizing the repayment terms of the \$5 million term loan from PNC Bank used by our wholly-owned BRLI No. 2 Acquisition Corp. subsidiary to fund the \$5 million acquisition cash payment in connection with its purchase of the operating assets of GeneDx, Inc. The term loan is evidenced by a secured promissory note payable over a six year term in equal

Edgar Filing: BIO REFERENCE LABORATORIES INC - Form 10-Q

monthly principal payments of approximately \$69, plus interest at an annual rate of 6.85%. The balance on this note as of April 30, 2008 is approximately \$3,750.

Pursuant to this agreement the Company made a cash payment to the prior owners of GeneDx as certain financial goals were achieved of \$1,917 and 11,548 shares of BRLI's common stock during the period ended January 31, 2008.

In January 2007, the Company issued a ten year term note of \$4,100 for the financing of equipment. The note is payable in equal monthly installments of approximately \$47 including principal and interest, with payment commencing on March 1, 2007 at an effective interest rate of 6.63% per annum. The balance on this note as of April 30, 2008 is approximately \$3,723.

In May of 2008, the Company executed a sixth amendment to the loan agreement with PNC Bank (1) increasing the maximum revolving advance limit to \$40,000 (2) increasing the capital expenditure limit to \$15,000 during any fiscal year and (3) extending the term until October 31, 2012.

We intend to expand our laboratory operations through aggressive marketing while also diversifying into related medical fields through acquisitions. These acquisitions may involve cash, notes, common stock, and/or combinations thereof.

Tabular Disclosure of Contractual Obligations

| | Over the Next | | |
|---------------------------------|---------------|----|--------|
| | Five Years | | FY2008 |
| Long - Term Debt | \$ 7,920 | \$ | 1,155 |
| Capital Leases | 4,917 | | 2,266 |
| Operating Leases | 3,290 | | 2,404 |
| Purchase Obligations | 34,941 | | 9,631 |
| Employment/Consultant Contracts | 8,895 | | 2,165 |
| Total | \$ 59,963 | \$ | 17,621 |

Our cash balance at April 30, 2008 totaled \$10,059 as compared to \$11,897 at October 31, 2007. We believe that our cash position, the anticipated cash generated from future operations, and the availability of our credit line with PNC Bank, will meet our anticipated cash needs in fiscal 2008.

Impact of Inflation - To date, inflation has not had a material effect on our operations.

New Authoritative Pronouncements

Edgar Filing: BIO REFERENCE LABORATORIES INC - Form 10-Q

In May 2008, FASB issued two new Financial Accounting Standards No. 162 *The Hierarchy of Generally Accepted Accounting Principles* and No. 163 *Accounting for Financial Guarantee Insurance Contracts* an interpretation of FASB Statement No. 60 .

FAS #162 identifies the sources of accounting principles and the framework for selecting the principles to be used in the preparation of financial statements of nongovernmental entities that are presented in conformity with generally accepted accounting principles (GAAP) in the United States (the GAAP hierarchy). It is This Statement is effective 60 days following the SEC's approval of the Public Company Accounting Oversight Board amendments to AU Section 411, *The Meaning of Present Fairly in Conformity With Generally Accepted Accounting Principles*. This statement is not expected to have a material impact on the reporting of our results of operations.

FAS #163 is primarily geared towards financial guarantee insurance contracts by insurance enterprises. It is not expected to have any material effect on the reporting of our results of operations.

In March 2008 FASB issued Financial Accounting Standards No. 161, *Disclosures about Derivative Instruments and Hedging Activities* an amendment of FASB Statement No. 133. This statement is effective for financial statements issued for fiscal years end interim periods beginning after November 15, 2008, with early application encouraged. This Statement changes the disclosure requirements for derivative instruments and hedging activities. This statement is not expected to have a material impact on the reporting of our results of operations.

In February 1, 2008, FASB issued FASB Staff Position (FSP) Fin 48-2. FSP FIN 48-2 amends FIN 48 to defer its effective date for nonpublic and pass through entities. This is not expected to have any effect on the Company's consolidated financial statements as the Company does not currently employ any pass through entities.

In December 2007, the FASB issued Financial Accounting Standards No. 160, *Noncontrolling Interests in Consolidated Financial Statements* an amendment of ARB No. 51. This statement is effective for fiscal years, and interim periods within those fiscal years, beginning on or after December 15, 2008, with earlier adoption prohibited. This statement requires the recognition of a noncontrolling interest (minority interest) as equity in the consolidated financial statements and separate from the parent's equity. The amount of net income attributable to the noncontrolling interest will be included in consolidated net income on the face of the income statement. It also amends certain of ARB No. 51's consolidation procedures for consistency with the requirements of SFAS 141(R). This statement also includes expanded disclosure requirements regarding the interests of the parent and its noncontrolling interest. We are currently evaluating this new statement and anticipate that the statement will not have a significant impact on the reporting of our results of operations.

Critical Accounting Policies

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reported periods.

Accounting for Goodwill

We evaluate the recoverability and measure the possible impairment of goodwill under SFAS 142, annually at the end of the fiscal year. The impairment test is a two-step process that begins with the estimation of the fair value of the reporting unit. The first step screens for potential

Edgar Filing: BIO REFERENCE LABORATORIES INC - Form 10-Q

impairment and the second step measures the amount of the impairment, if any. Management's estimate of fair value considers publicly available information regarding our market capitalization as well as (i) publicly available information regarding comparable publicly-traded companies in the clinical laboratory testing industry, (ii) the financial projections and future prospects of our business, including its growth opportunities and likely operational improvements, and (iii) comparable sales prices, if available. As part of the first step to assess potential impairment, management compares the estimate of fair value to book value of the Company's consolidated net assets. If the book value of the consolidated net assets is greater than the estimate of fair value, we then proceed to the second step to measure the impairment, if any. The second step compares the implied fair value of goodwill with its carrying value.

The implied fair value is determined by allocating the fair value of the reporting unit to all of the assets and liabilities of that unit as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the purchase price paid to acquire the reporting unit. The excess of the fair value of the reporting unit over the amounts assigned to its assets and liabilities is the implied fair value of goodwill. If the carrying amount of the goodwill is greater than its implied fair value, an impairment loss will be recognized in that period.

Accounting for Intangible and Other Long-Lived Assets

We evaluate the possible impairment of our long-lived assets, including intangible assets. We review the recoverability of our long-lived assets when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. Evaluation of possible impairment is based on our ability to recover the asset from the expected future pretax cash flows (undiscounted and without interest charges) of the related operations. If the expected undiscounted pretax cash flows are less than the carrying amount of such asset, an impairment loss is recognized for the difference between the estimated fair value and carrying amount of the asset.

Accounting for Revenue

Service revenues are principally generated from laboratory testing services including chemical diagnostic tests such as blood analysis, urine analysis and genetic testing among others. Net service revenues are recognized at the time the testing services are performed and are reported at their estimated net realizable amounts. These estimated net realizable amounts from patients, third party payors and others for services rendered are accrued on an estimated basis in the period the related services are rendered and adjusted in subsequent periods based upon an analysis of the Company's collection experience from each category of payor group as well as prospectively determined contractual adjustments and discounts with third party payors. Differences between these adjustments and any subsequent revisions are included in the statement of operations in which the revisions are made and are disclosed, if material. Applying this methodology and aggregating its collection experience from all payor groups, the Company has not been required to record an adjustment related to revenue recorded in prior periods that was material in nature.

Accounting for Contractual Credits and Doubtful Accounts

An allowance for contractual credits is determined based upon a review of the reimbursement policies and subsequent collections for the different types of payors. Agings of accounts receivable are monitored by billing personnel and follow-up activities are conducted as necessary. Bad debt expense is recorded within selling, general and administrative expenses as a percentage of sales considered necessary to maintain the allowance for doubtful accounts at an appropriate level, based on our experience with our accounts receivable. We write off accounts against the allowance for doubtful accounts when they are deemed to be uncollectible. For client billing, accounts are written off when all reasonable collection efforts prove to be unsuccessful. Patient accounts are written off after the normal dunning cycle has occurred, which may include being transferred to a third party collection agency. Third party accounts are written off when they exceed the payer's timely filing limits.

Accounting for Income Taxes

We account for income taxes utilizing the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and for tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to

Edgar Filing: BIO REFERENCE LABORATORIES INC - Form 10-Q

taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Future tax benefits, such as net operating loss carryforwards, are recognized to the extent that realization of such benefits is more likely than not.

Forward Looking Statements

This Quarterly Report on Form 10-Q contains historical information as well as forward-looking statements. Statements looking forward in time are included in this Quarterly Report pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks and uncertainties that may cause our actual results in future periods to be materially different from any future performance suggested herein.

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the reported amounts of revenues and expenses during the reporting period. While many aspects of our business are subject to complex federal, state and local regulations, the accounting for our business is generally straightforward. Our revenues are primarily comprised of a high volume of relatively low dollar transactions, and about 42% of all our costs consist of employee compensation and benefits. Revenues are recognized at the time the services are performed and are reported at the estimated net realizable amounts from patients, third-party payors and others for services rendered including prospectively determined adjustments under reimbursement agreements with third-party payors. These adjustments are accrued on an estimated basis in the period the services are rendered and adjusted in future periods as final settlements are determined. These estimates are reviewed and adjusted, if warranted, by senior management on a monthly basis. We believe that our estimates and assumptions are correct; however, several factors could cause actual results to differ materially from those currently anticipated due to a number of factors in addition to those discussed under the caption Risk Factors contained in Item 1A of our Annual Report on Form 10-K for the year ended October 31, 2007, as well as elsewhere herein including:

- our failure to integrate newly acquired businesses (if any) and the cost related to such integration.
- our failure to obtain and retain new customers and alliance partners, or a reduction in tests ordered or specimens submitted by existing customers.
- adverse results from investigations of clinical laboratories by the government, which may include significant monetary damages and/or exclusion from the Medicare and Medicaid programs.
- loss or suspension of a license or imposition of a fine or penalties under, or future changes in, the law or regulations of CLIA-88, or those of Medicare, Medicaid or other federal, state or local agencies.
- failure to comply with the Federal Occupational Safety and Health Administration requirements and the recently passed Needlestick Safety and Prevention Act.
- failure to comply with HIPAA, which could result in significant fines as well as substantial criminal penalties.
- changes in payor mix.
- failure to maintain acceptable days sales outstanding levels.
- increased competition, including price competition.
- our ability to attract and retain experienced and qualified personnel.

- adverse litigation results.
- liabilities that result from our inability to comply with new corporate governance requirements.
- failure to comply with the Sarbanes-Oxley Act of 2002.

Item 3 - QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We do not invest in or trade market risk sensitive instruments. We also do not have any foreign operations or significant foreign sales so that our exposure to foreign currency exchange rate risk is minimal.

We do have exposure to both rising and falling interest rates. At April 30, 2008, advances of approximately \$568 under our Loan Agreement with PNC Bank were subject to interest charges at the Bank's then prime rate of 5%. In addition, we elected to have the remaining \$20,000 of advances outstanding at said date converted into a Eurodollar rate loan with a variable interest rate of 4.41%.

We estimate that our monthly cash interest expense at April 30, 2008 was approximately \$200 and that a one percentage point increase or decrease in short-term rates would increase or decrease our monthly interest expense by approximately \$18.

Item 4 - CONTROLS AND PROCEDURES

An evaluation was carried out under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of the Company's disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report. Based upon that evaluation, our principal executive officer and principal financial officer concluded that those disclosure controls and procedures were effective to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission's rules and forms.

PART II - OTHER INFORMATION

Item 6

EXHIBITS

- 31A Certification of Chief Executive Officer
- 31B Certification of Chief Financial Officer
- 32A Certification Pursuant to 18 U.S.C. Section 1350 of Chief Executive Officer
- 32B Certification Pursuant to 18 U.S.C. Section 1350 of Chief Financial Officer

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BIO-REFERENCE LABORATORIES, INC.
(Registrant)

/S/ Marc D. Grodman, M.D.
Marc D. Grodman, M.D.
President and Chief Executive Officer

/S/ Sam Singer
Sam Singer
Chief Financial and Accounting Officer

Date: June 6, 2008